Zhangjun Cheng

2.1k total citations · 1 hit paper
65 papers, 1.4k citations indexed

About

Zhangjun Cheng is a scholar working on Surgery, Molecular Biology and Cancer Research. According to data from OpenAlex, Zhangjun Cheng has authored 65 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Surgery, 25 papers in Molecular Biology and 21 papers in Cancer Research. Recurrent topics in Zhangjun Cheng's work include Cholangiocarcinoma and Gallbladder Cancer Studies (26 papers), Cancer-related molecular mechanisms research (13 papers) and Gallbladder and Bile Duct Disorders (12 papers). Zhangjun Cheng is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (26 papers), Cancer-related molecular mechanisms research (13 papers) and Gallbladder and Bile Duct Disorders (12 papers). Zhangjun Cheng collaborates with scholars based in China, Germany and Hong Kong. Zhangjun Cheng's co-authors include Yong Xia, Jiahua Zhou, Feng Shen, Kui Wang, Anfeng Si, Pinghua Yang, Zhengqing Lei, Norbert Hüser, Jun Li and Tian Yang and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Hepatology.

In The Last Decade

Zhangjun Cheng

60 papers receiving 1.4k citations

Hit Papers

Circular RNA ACTN4 promotes intrahepatic cholangiocarcino... 2021 2026 2022 2024 2021 50 100 150

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhangjun Cheng China 20 560 474 452 396 296 65 1.4k
Maristella Bianconi Italy 20 416 0.7× 402 0.8× 191 0.4× 144 0.4× 558 1.9× 59 1.2k
Bingyi Lin China 18 455 0.8× 183 0.4× 100 0.2× 101 0.3× 190 0.6× 48 910
Qiang Qu China 22 498 0.9× 226 0.5× 338 0.7× 407 1.0× 422 1.4× 53 1.5k
Yuqi Wang China 19 335 0.6× 104 0.2× 148 0.3× 357 0.9× 98 0.3× 49 1.3k
Hongliang Sun China 20 723 1.3× 386 0.8× 201 0.4× 162 0.4× 248 0.8× 67 1.5k
Tsunekazu Oikawa Japan 19 482 0.9× 159 0.3× 414 0.9× 371 0.9× 221 0.7× 61 1.3k
Alessandro Bittoni Italy 23 437 0.8× 479 1.0× 170 0.4× 288 0.7× 935 3.2× 93 1.5k
Dongmei Ji China 15 392 0.7× 130 0.3× 120 0.3× 163 0.4× 539 1.8× 92 1.2k

Countries citing papers authored by Zhangjun Cheng

Since Specialization
Citations

This map shows the geographic impact of Zhangjun Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhangjun Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhangjun Cheng more than expected).

Fields of papers citing papers by Zhangjun Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhangjun Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhangjun Cheng. The network helps show where Zhangjun Cheng may publish in the future.

Co-authorship network of co-authors of Zhangjun Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Zhangjun Cheng. A scholar is included among the top collaborators of Zhangjun Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhangjun Cheng. Zhangjun Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Liangtao, et al.. (2024). Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances. Pharmaceuticals. 17(12). 1724–1724. 7 indexed citations
3.
Cheng, Zhangjun, et al.. (2023). miR-552 promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma by targeting FOXO1. Experimental Cell Research. 431(1). 113741–113741.
4.
Zhang, Jingwei, Zhiqiang Cai, Chen Chen, et al.. (2023). A Bayesian Network Prediction Model for Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma: A Multi‐institutional Study. World Journal of Surgery. 47(3). 773–784. 5 indexed citations
5.
Liu, Yixuan, Qi Sun, Chengfei Zhang, et al.. (2023). STING-IRG1 inhibits liver metastasis of colorectal cancer by regulating the polarization of tumor-associated macrophages. iScience. 26(8). 107376–107376. 21 indexed citations
6.
Zhu, Qian, Zhengqing Lei, Chang Xu, et al.. (2023). LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy. Cancer Medicine. 12(13). 14526–14544. 11 indexed citations
7.
Yang, Pinghua, Fei Teng, Yong Xia, et al.. (2022). Liver resection versus liver transplantation for hepatocellular carcinoma within the Milan criteria based on estimated microvascular invasion risks. Gastroenterology report. 11. goad035–goad035. 5 indexed citations
8.
Han, Tao, Hao Zheng, Jin Zhang, et al.. (2022). Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis. Cell Death and Disease. 13(3). 200–200. 30 indexed citations
9.
Lei, Zhengqing, Nuo Cheng, Anfeng Si, et al.. (2022). A Novel Nomogram for Predicting Postoperative Liver Failure After Major Hepatectomy for Hepatocellular Carcinoma. Frontiers in Oncology. 12. 817895–817895. 10 indexed citations
10.
Chen, Chen, Hong Wu, Tianqiang Song, et al.. (2022). Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study. BMC Cancer. 22(1). 329–329. 12 indexed citations
11.
Chen, Qinjunjie, Haibo Wang, Zheng Li, et al.. (2021). Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. Journal of Hepatology. 76(1). 135–147. 171 indexed citations breakdown →
12.
Lei, Zhengqing, Anfeng Si, Pinghua Yang, et al.. (2021). External Validation of Six Liver Functional Reserve Models to predict Posthepatectomy Liver Failure after Major Resection for Hepatocellular Carcinoma. Journal of Cancer. 12(17). 5260–5267. 7 indexed citations
13.
Lei, Zhengqing, Anfeng Si, Pinghua Yang, et al.. (2020). microRNA-454 promotes liver tumor-initiating cell expansion by regulating SOCS6. Experimental Cell Research. 390(1). 111955–111955. 9 indexed citations
14.
Si, Anfeng, Jun Li, Zhishi Yang, et al.. (2019). Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology. 26(6). 1841–1850. 61 indexed citations
15.
Wang, Baocai, Benedikt Kaufmann, Thomas Engleitner, et al.. (2019). Brg1 promotes liver regeneration after partial hepatectomy via regulation of cell cycle. Scientific Reports. 9(1). 2320–2320. 25 indexed citations
16.
Cheng, Zhangjun, Zhengqing Lei, & Feng Shen. (2019). Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma?. Cancer Letters. 460. 10–17. 8 indexed citations
17.
Cheng, Zhangjun, Zhengqing Lei, Pinghua Yang, et al.. (2018). Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway. Gene. 684. 95–103. 37 indexed citations
18.
Zhou, Jiahua, et al.. (2015). Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells. Tumor Biology. 36(8). 6173–6179. 51 indexed citations
19.
Kemter, Andrea M., Stefanie Scheu, Norbert Hüser, et al.. (2015). The cannabinoid receptor 2 is involved in acute rejection of cardiac allografts. Life Sciences. 138. 29–34. 7 indexed citations
20.
Yang, Fei, et al.. (2009). Expression and Clinical Significance of P120 Catenin mRNA and Protein in Pancreatic Carcinoma. Bosnian Journal of Basic Medical Sciences. 9(3). 191–197. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026